[Management of gynecomastia induced by bicalutamide].
Adjuvant bicalutamide monotherapy after radical prostatectomy improves the overall survival in patients with locally advanced prostate cancer. The main adverse event of the nonsteroidal antiandrogen is the development of gynecomastia against which prophylactic breast irradiation can be administered. Therapeutic local radiotherapy using a very small number of fractions is a well-tolerated management option. Symptom improvement is observed in about half of the patients. Radiotherapy-related adverse effects are often mild (erythema, skin irritation) and transient. Tamoxifen has been also shown to be effective in prevention and treatment of gynecomastia induced by adjuvant therapy by bicalutamide in two-third of patients. Long-term safety of this prophylactic and therapeutic approach needs to be investigated through appropriate trials. Further evaluation of the optimal dose and duration of treatment with tamoxifen in this setting is required.
Haddad
E
E
Clinique Hartmann, 26, boulevard Victor-Hugo, 92200 Neuilly-sur-Seine, France. elie.haddad@free.fr
D000726:Androgen Antagonists / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006177:Gynecomastia / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009570:Nitriles / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014105:Tosyl Compounds / Q000009:adverse effects*
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide